Dr David Warren Boxwell, MD in Norwich, CT - General Practice

Dr David Warren Boxwell, MD is a General Practice physician based in Norwich, Connecticut. Dr David Warren Boxwell is licensed to practice in Connecticut (license number 19531) and his current practice location is 67 Church St., Suite 300, Norwich, Connecticut. He can be reached at his office (for appointments etc.) via phone at (860) 884-6855.

NPI number for Dr David Warren Boxwell is 1225510571 and his current mailing address is 9 Park St Apt 25, Stafford Springs, Connecticut. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1225510571.

Contact Information

	Dr David Warren Boxwell, MD
	67 Church St., Suite 300, Norwich, CT 06360-0636
	(860) 884-6855
	Not Available

Physician's Profile

Full Name	Dr David Warren Boxwell
Gender	Male
Speciality	General Practice
Location	67 Church St., Norwich, Connecticut
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1225510571
Provider Enumeration Date: 09/04/2018
Last Update Date: 09/04/2018

Medical Identifiers

Medical identifiers for Dr David Warren Boxwell such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1225510571	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	19531 (Connecticut)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr David Warren Boxwell is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr David Warren Boxwell, MD 9 Park St Apt 25, Stafford Springs, CT 06076-1380 Ph: (860) 315-4931	Dr David Warren Boxwell, MD 67 Church St., Suite 300, Norwich, CT 06360-0636 Ph: (860) 884-6855

News Archive

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections.

Community support critical for reducing childhood obesity

Community support of school obesity prevention programs is critical to achieving a significant decrease in obesity among children, according to researchers at the Michael & Susan Dell Center for Advancement of Healthy Living, which is part of The University of Texas Health Science Center at Houston (UTHealth).

Schizophrenia gene found to control the birth of new neurons

A gene that is arguably the most studied "schizophrenia gene" plays an unanticipated role in the brain: It controls the birth of new neurons in addition to their integration into existing brain circuitry, according to a report in the March 20th issue of the journal Cell, a Cell Press publication.

Blog summarizes analyses examining possible effects of sequestration on global health, science research

The Global Health Technologies Coalition's "Breakthroughs" blog examines "the likely devastating impact of sequestration on U.S.-funded global health, research, science, and development programs" and summarizes several recently released reports on potential budget cuts.

Update on Celsion's ThermoDox Phase III "HEAT" trial for HCC

Celsion Corporation, a leading oncology drug development company, today provided an update on the progress of its pivotal ThermoDox® Phase III "HEAT" trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Following recent regulatory approvals in China, Malaysia, Thailand and the Philippines, the study is now enrolling patients in eleven countries, with the majority of clinical sites located in the Asia Pacific region where HCC is most prevalent.

Dr David Warren Boxwell, MD - General Practice in Norwich, CT